Adagene gets NMPA clearance for HER2xCD3 bispecific ADG138
China's drug regulator cleared the IND for the double-masked T-cell engager, with a first-in-human Phase 1 study expected to start in China in the fourth quarter of 2026.
SEC filing
Latest
3 stories
Tuesday, September 22
Thursday, September 10
Adagene reports two collaboration milestones with Third Arc Bio and Exelixis
Adagene disclosed a lead candidate selection under its expanded Third Arc Bio deal and a $2.0 million preclinical milestone payment from Exelixis tied to its SAFEbody platform.
SEC filing (2)
Wednesday, August 12
Adagene reports mid-2026 results, muzastotug data across CRC and HCC trials
The company reported $127.9 million in cash and updated Phase 1b/2 data for its lead antibody muzastotug in colorectal and liver cancer.
SEC filing